A Phase I Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 Following Single and Multiple Ascending Dose Administration in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Prospective, Non-interventional Cohort Study
Latest Information Update: 24 Jul 2025
At a glance
Most Recent Events
- 24 Jul 2025 Status changed from not yet recruiting to recruiting.
- 11 Jul 2025 Planned End Date changed from 1 May 2026 to 30 Apr 2026.
- 11 Jul 2025 Planned primary completion date changed from 1 May 2026 to 30 Apr 2026.